BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 11585867)

  • 1. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
    Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
    J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
    J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
    Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
    Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
    Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
    Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
    Slavin-Chiorini DC; Kashmiri SV; Schlom J; Calvo B; Shu LM; Schott ME; Milenic DE; Snoy P; Carrasquillo J; Anderson K
    Cancer Res; 1995 Dec; 55(23 Suppl):5957s-5967s. PubMed ID: 7493377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody.
    Pietersz GA; Patrick MR; Chester KA
    J Nucl Med; 1998 Jan; 39(1):47-56. PubMed ID: 9443738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody.
    Beresford GW; Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Int J Cancer; 1999 Jun; 81(6):911-7. PubMed ID: 10362138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.
    Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK
    J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo comparison of binding of 99m-Tc-labeled anti-CEA MAb F33-104 with 99m-Tc-labeled anti-CEA MAb BW431/26.
    Watanabe N; Oriuchi N; Sugiyama S; Kuroki M; Matsuoka Y; Tanada S; Murata H; Inoue T; Sasaki Y
    Nuklearmedizin; 1999; 38(4):115-9. PubMed ID: 10392376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
    Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
    Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.
    Chinn PC; Morena RA; Santoro DA; Kazules T; Kashmiri SV; Schlom J; Hanna N; Braslawsky G
    Cancer Biother Radiopharm; 2006 Apr; 21(2):106-16. PubMed ID: 16706631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
    Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.